DNA vector and transformed tumor cell vaccines
Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.
1. A membrane anchoring protein comprising the amino acid sequence SEQ ID NO: 5 located within the N-terminal signal sequence and the C-terminal anchor region of the protein.
2. The membrane anchoring protein of claim 1 wherein the membrane anchoring protein is a bacterial protein.
3. The membrane anchoring protein of claim 1 wherein the helical N-terminal signal peptide region of the protein orients inside to outside to provide egress to the cell membrane surface.
4. The membrane anchoring protein of claim 1 wherein the helical C-terminal anchor region is oriented outside to inside orientation on the cell membrane.
5. The membrane anchoring protein of claim 1 wherein the amino acid sequence within the N-terminal signal sequence has the amino acid sequence of SEQ ID NO: 7.
6. The membrane anchoring protein of claim 1 wherein the amino acid sequence within the C-terminal anchor region of the protein has the amino acid sequence of SEQ ID NO: 9.
7. The membrane anchoring protein of claim 1 wherein the protein induces an immune response in vivo.
8. The membrane anchoring protein of claim 7 wherein the protein is a streptococcal protein.
9. The membrane of claim 1 which is cell membrane.
10. The cell membrane of claim 9 which is a eukaryotic membrane.
11. The cell membrane of claim 9 which is a prokaryotic membrane.